A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...